Key facts
- iCardio.ai’s last known valuation is $330K (May 2023).
- It has raised $1.4M; the latest was Later Stage VC in Apr 2026.
- Notable investors include Techstars, CONNECT (San Diego), The Roddenberry Foundation, BSD Enterprises, BeyondBio (Isarel) — 13 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 13 names
- ·Watchlist + deal alerts for iCardio.ai
- ·The full record, as it builds
Funding rounds
No funding rounds for iCardio.ai are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About iCardio.ai
Developer of deep-learning echo tools designed for echocardiographic analysis. The company's models are based on segmentation, classification, regression analysis, and artificial intelligence for the interpretation of ultrasound imaging, with a focus on echocardiograms, enabling ultrasound companies to research and development of AI algorithms and offering a custom application for the interpretation of ultrasound imaging.
- Sector
- Healthcare
- HQ
- Los Angeles, CA, United States
- Founded
- 2018
- Employees
- 20
- Website
- icardio.ai/
- Ownership
- Privately Held (backing)
iCardio.ai doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in iCardio.ai shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on iCardio.ai in its N-PORT filings yet. We sweep new filings monthly.